GLP-1 Litigation Reaches 4,400+ Lawsuits as Bellwether Trials Approach

Litigation against GLP-1 drug manufacturers has reached a significant milestone. At least 4,400 patients have filed lawsuits alleging Ozempic, Wegovy, and Mounjaro caused severe gastrointestinal injuries and vision loss, according to USA Today's analysis of consolidated federal and state litigation. With 75% of federal cases alleging gastroparesis (a condition where the stomach fails to empty properly) and bellwether trials scheduled for mid-2026, law firms are preparing case files for judicial scrutiny.

The litigation targets medications prescribed to more than 31 million Americans. A KFF poll identified that 12% of U.S. adults take a GLP-1 medication for weight loss, diabetes, or related conditions, creating one of the largest potential claimant populations in recent pharmaceutical litigation.

Scientific Research Underlying the Claims

The claims rely on peer-reviewed epidemiological research. A 2023 JAMA study found GLP-1 users face elevated risks compared to users of other weight loss medications: a 3.67 times higher risk of gastroparesis, a 4.22 times higher risk of bowel obstruction, and a 9.09 times higher risk of pancreatitis.

Additionally, a Harvard study published in JAMA Ophthalmology in July 2024 reported an association between semaglutide (the active ingredient in Ozempic and Wegovy) and non-arteritic anterior ischemic optic neuropathy (NAION). The risk was 4.28 times higher for diabetic patients and 7.64 times higher for weight loss patients.

Plaintiffs argue these risks required earlier and more specific warnings. "We think that the full panoply of conditions that this set of drugs can cause are not fully warned of," Jonathan Orent, co-lead counsel for plaintiffs in the MDL, told USA Today.

Two MDLs, Two Injury Categories

The litigation proceeds in parallel federal forums. MDL 3094, established in February 2024 in the Eastern District of Pennsylvania, consolidates gastrointestinal injury claims. A second proceeding, MDL 3163, was created in December 2025 specifically for NAION vision loss claims.

According to court filings cited by USA Today, the distribution of claims in the GI litigation includes:

• 75% alleging gastroparesis
• 18% alleging ileus
• 18% alleging intestinal obstructions
• 8% alleging gallbladder injuries requiring surgery
• 110+ plaintiffs alleging severe vision impairment or blindness

Court-Ordered Diagnostic Standards

An August 2025 case management order established specific evidentiary thresholds for the GI docket. Judge Karen S. Marston ruled that plaintiffs alleging gastroparesis must present objective diagnostic testing: gastric emptying scintigraphy, a validated breath test, or a wireless motility capsule study performed during the diagnostic workup.

The court excluded claims supported only by self-reported symptoms or unconfirmed clinical suspicion. Studies indicated retained gastric food on endoscopy has variable diagnostic accuracy, making formal motility testing mandatory.

Vision Loss Claim Requirements

For NAION lawsuits in MDL 3163, documentation requires ophthalmology records establishing sudden visual field loss, ruling out giant cell arteritis or other etiologies, and confirming the temporal sequence between GLP-1 administration and symptom onset.

Evidentiary Preparation for 2026

With bellwether trials scheduled for mid-2026, case selection depends on complete records. According to MDL Update, expert discovery closes in spring 2026 with dispositive motions to follow.

Record Collection Scope

A typical GLP-1 claimant file involves records across several healthcare settings:

• Prescribing physicians (primary care, endocrinologists, or bariatric specialists)
• Retail and mail-order pharmacies verifying dispense dates and dosages
• Gastroenterologists who performed gastric emptying studies
• Emergency departments and hospitals for acute episodes and admissions
• Ophthalmologists and neuro-ophthalmologists for vision loss claims

LlamaLab retrieves records in 4 days on average (with ~30-40% returned same-day on electronic requests) and uses insurance data to surface treatment locations clients don't always remember. Invoices are itemized per case to flow through as recoverable case disbursements on settlement statements.

Summary

The GLP-1 litigation has grown to over 4,400 consolidated cases across two federal MDLs. With tens of millions of active prescriptions nationwide and bellwether proceedings approaching, case viability depends on objective diagnostic documentation and verified exposure histories.

Sources: USA Today, JAMA, JAMA Ophthalmology, FDA, Reuters, KFF, MDL Update, Drugwatch, About Lawsuits.